 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7457 News |  |
| «12...86878889909192939495969798 |
- ||| Zomacton (somatropin) / Ferring
Trial completion, Compliance: Evaluation of Overall Compliance and Duration of Zomacton (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=87, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy (clinicaltrials.gov) - Feb 1, 2012
P3, N=386, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 29, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 25, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
- | Firmagon (degarelix) / Astellas, Ferring
New P4 trial: FIT: Firmagon (Degarelix) Intermittent Therapy (clinicaltrials.gov) - Jan 17, 2012
P4, N=144, Recruiting, Sponsor: Canadian Urology Research Consortium
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long Term Safety Study of Degarelix in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 9, 2012
P3, N=77, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cervidil (dinoprostone) / Ferring
Enrollment change: Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM) (clinicaltrials.gov) - Jan 4, 2012
P4, N=70, Completed, Sponsor: Liverpool Women's NHS Foundation Trust
Active, not recruiting --> Completed N=100 --> 70
- Cervidil (dinoprostone) / Ferring
Trial completion: Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM) (clinicaltrials.gov) - Jan 4, 2012
P4, N=70, Completed, Sponsor: Liverpool Women's NHS Foundation Trust
N=100 --> 70 Recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
- | Firmagon (degarelix) / Astellas, Ferring
Trial termination: A Degarelix Trial in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 19, 2011
P3, N=288, Terminated, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 14, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data. Initiation date: Sep 2011 --> Dec 2011
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=100, Active, not recruiting, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Initiation date: Sep 2011 --> Dec 2011 Recruiting --> Active, not recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=127, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 12, 2011
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=76, Completed, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Trial completion: Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening. (clinicaltrials.gov) - Dec 11, 2011
P4, N=210, Completed, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer (clinicaltrials.gov) - Dec 7, 2011
P3, N=246, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer (clinicaltrials.gov) - Dec 6, 2011
P3, N=157, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | FSH-GEX (follicle stimulating hormone) / Glycotope
Trial completion: Single Dose FSH-GEX (clinicaltrials.gov) - Nov 24, 2011
P1, N=18, Completed, Sponsor: Glycotope GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| FSH-GEX (follicle stimulating hormone) / Glycotope
New P1 trial: Multiple Dose FSH-GEX(TM) in Healthy Volunteers (clinicaltrials.gov) - Nov 20, 2011
P1, N=57, Completed, Sponsor: Glycotope GmbH
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 17, 2011
P3, N=3, Terminated, Sponsor: UCB, Inc.
Suspended --> Terminated; Termination of study due to low enrollment. There were no safety issues.
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 17, 2011
P3, N=3, Terminated, Sponsor: UCB, Inc.
There were no safety issues. N=50 --> 3
- Cervidil (dinoprostone) / Ferring
Trial completion: Prostaglandin E2 in Migraine Suffers Without Aura. (clinicaltrials.gov) - Nov 7, 2011
P=N/A, N=12, Completed, Sponsor: Troels Wienecke
N=50 --> 3 Recruiting --> Completed
- | Testavan (transdermal testosterone gel 2%) / Ferring
New P2 trial: A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator (clinicaltrials.gov) - Nov 2, 2011
P2, N=20, Completed, Sponsor: Ferring Pharmaceuticals
- | Glypressin (terlipressin) / Ferring
Trial completion: Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=20, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, New P3 trial: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (clinicaltrials.gov) - Oct 11, 2011
P3, N=316, Active, not recruiting, Sponsor: Astellas Pharma Inc
- Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy (clinicaltrials.gov) - Oct 3, 2011
P2, N=50, Recruiting, Sponsor: British Columbia Cancer Agency
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 27, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
- Bravelle (urofollitropin) / Ferring
Trial completion: Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial (clinicaltrials.gov) - Sep 20, 2011
P4, N=232, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- ||||| Rekovelle (follitropin delta) / Ferring
New P2 trial: A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment (clinicaltrials.gov) - Aug 29, 2011
P2, N=265, Completed, Sponsor: Ferring Pharmaceuticals
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: RAPID-axSpA: Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (clinicaltrials.gov) - Aug 25, 2011
P3, N=325, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Testavan (transdermal testosterone gel 2%) / Ferring
Trial completion: Efficacy, Pharmacokinetics and Safety of Testosterone (clinicaltrials.gov) - Aug 15, 2011
P2, N=20, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| Menopur (menotropin) / Ferring, Bravelle (urofollitropin) / Ferring
New P4 trial: Menopur Mixed Protocol (clinicaltrials.gov) - Aug 14, 2011
P4, N=122, Completed, Sponsor: Ferring Pharmaceuticals